Skip to main content
. 2024 Sep 15;14(9):4523–4536. doi: 10.62347/DVXL1377

Figure 1.

Figure 1

Sensitivity and pERK suppression in human CRC cell lines to MRTX as a function of KRAS mutation status. Cell viability assays with increasing MRTX1133 doses used to treat colorectal cancer cell lines with different KRAS mutations. The viability assays were performed using the CellTiterGlo assay. Western blots show expression of pERK and Ran with increasing doses of MRTX in the colorectal tumor cell lines as indicated. Ran was used as a loading control.